Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

Investors warm up to the idea of Pfizer snapping up GSK

Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea.

Betting on Pfizer merger--or CEO goodbye--traders go bullish on Glaxo

Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea. As Bloomberg reports, options traders are paying record prices for bullish GSK options--and this after the British drugmaker lost $11 billion off its market cap in less than three months.

World Health Assembly passes resolution on vaccine pricing, transparency

The World Health Assembly passed a resolution Monday calling for improved vaccine pricing transparency and for more affordable vaccines, with more than 60 countries expressing support.

Atlas' Padlock scoops up some GlaxoSmithKline assets in autoimmunity

Padlock Therapeutics, an Atlas Venture-seeded biotech startup, grabbed the rights to some potential drugs developed by GlaxoSmithKline, widening its arsenal of assets as it chases a novel approach to autoimmune disease.

Post-swap Novartis preps cancer drug R&D road show

Two of the cancer drugs Novartis traded for from GSK--Tafinlar and Mekinist--will post combo survival data at ASCO.

GSK, Pfizer among Big Pharmas bailing on Chinese sales as provinces squeeze prices

When China said it would lift price caps on drugs, the move was heralded as welcome relief for drugmakers. But as Bloomberg reports, the optimism may have been premature. Yes, the price caps won't affect most drugs beginning June 1. But foreign drugmakers are facing pressure to cut their prices voluntarily--more than ever.

Investors: GSK chief Witty is safe for now, but one more strike and he's out

As GlaxoSmithKline charts a new course to return to growth, investors are willing to give CEO Andrew Witty some time to see it through.

Pfizer could buy GSK, but would Shire or Perrigo offer better targets?

The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.

ProPublica: Safety questions over GSK's Advair linger after years on the asthma throne

U.S. regulators gave GlaxoSmithKline's Advair the green light a decade and a half ago, paving the way for a long reign that saw the med grow to more than $8 billion in annual sales. But even after all these years, whether Advair poses a higher risk of asthma-related death remains unclear, ProPublica says.

Should Pfizer snap up GSK? Well, a megadeal could speed up a split

Pfizer needs to make a deal--or several. It's obviously amenable to another megamerger, given that it tried to snap up AstraZeneca for more than $100 billion last year. So why not GlaxoSmithKline?